Samsung Bioepis receives approval from the European Commission for the Enbrel Biosimilar, Benepali.
Samsung Bioepis, the joint venture between Biogen and Samsung BioLogics, announced on Jan. 16, 2016 that the company has been granted European Commission (EC) approval for Benepali, an etanercept biosimilar referencing Enbrel. Benepali has been granted marketing authorization in the European Union (EU) for the treatment of adults with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, non-radiographic axial spondyloarthritis, and plaque psoriasis. Biogen intends to make Benepali available for patients in the coming weeks.
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available. Anti-TNFs are the largest component of the EU biologics market, accounting for approximately $10 billion of all biologics sold.
The EC approval was based on a preclinical and clinical data package submitted to the European Medicines Agency by Samsung Bioepis. Confirmatory data from head-to-head Phase I and Phase III clinical trials compared Benepali to its reference product Enbrel.
Source: Biogen
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.